Your browser doesn't support javascript.

Biblioteca Virtual em Saúde

Brasil

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

Alitretinoin can be a good treatment option for idiopathic recalcitrant trachyonychia in adults: an open-label study.

Shin, K; Kim, T-W; Park, S-M; Lee, H-J; Jin, H; You, H-S; Shim, W-H; Kim, G-W; Kim, H-S; Ko, H-C; Kim, B-S; Kim, M-B.
J Eur Acad Dermatol Venereol; 32(10): 1810-1814, 2018 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-29704273

BACKGROUND:

Trachyonychia can be refractory to conventional treatments including topical, intralesional or systemic corticosteroids, as well as cyclosporine and retinoids. Therefore, new treatment options are needed for recalcitrant trachyonychia.

OBJECTIVE:

To evaluate the efficacy and safety of oral alitretinoin for idiopathic recalcitrant trachyonychia.

METHODS:

A total of 21 adult patients with 210 nails affected by idiopathic recalcitrant trachyonychia were evaluated in this open-label prospective study. All patients took 30 mg of alitretinoin daily for at least 3 months. Clinical outcomes were assessed using the Physician Global Assessment (PGA) scale proposed by Park et al. (degree of roughness: 0, clear; 1, mild; 2, moderate; 3, marked; 4, severe) at baseline and 1, 3 and 6 months after treatment.

RESULTS:

After 1, 3 and 6 months of treatment, 74.3% (123/210), 98.1% (206/210) and 99.2% (119/120) of nails showed clinical improvement, respectively; 0% (0/210), 22.9% (48/210) and 69.2% (83/120) were completely free from nail abnormalities. The mean PGA score at baseline was 3.4, decreasing significantly to 2.7, 1.3 and 0.7 at 1, 3 and 6 months following treatment, respectively.

LIMITATIONS:

A small number of participants and lack of a control group were limitations.

CONCLUSIONS:

For the first time, this study evaluated the efficacy and safety of oral alitretinoin for idiopathic recalcitrant trachyonychia in adults. The results suggest that oral alitretinoin can be a good treatment option for adult patients with recalcitrant trachyonychia.
Selo DaSilva